SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03998111

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

The Role of Genetic Variation in CLTCL1 and Other Related Genes in Relation to Whole-body Glucose Control: A Pilot Study

Maintaining stable blood glucose concentrations after eating has important implications for health. Individuals who are better able to maintain stable blood glucose concentrations after consuming carbohydrate have a lower risk of mortality from cardiovascular disease. Muscle is the primary tissue for glucose disposal following a meal, and responsiveness of this tissue to insulin is dictated by GLUT4 translocation to the muscle cell membrane. Clathrin heavy chain isoform 22 (CHC22) is a protein that plays a key role in intracellular GLUT4 action, and it may play an important role in whole-body glucose control. Genetic variation in the gene which codes for CHC22 may be able to explain differences in glucose control at the whole-body level.

NCT03998111 Glucose Control

1 Interventions

Name: Oral glucose tolerance test

Description: Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.

Type: Diagnostic Test

Trial


Primary Outcomes

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by CHC22 genotype.

Measure: Plasma glucose incremental area under the curve (CHC22 genotype)

Time: 2 hours

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the peak glucose concentration will be measured, this will be grouped by CHC22 genotype.

Measure: Peak plasma glucose (CHC22 genotype)

Time: 2 hours

Secondary Outcomes

Description: Plasma glucose will be measured at baseline and will be grouped by CHC22 genotype.

Measure: Fasting plasma glucose concentrations (CHC22 genotype)

Time: 2 hours

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by genotyping other genes related to glucose control or sweet taste sensitivity.

Measure: Plasma glucose incremental area under the curve (other genotypes)

Time: 2 hours

Description: Plasma glucose will be measured at baseline and will be grouped by genotypes related to glucose control and sweet taste sensitivity.

Measure: Fasting plasma glucose concentrations (other genotypes)

Time: 2 hours

Description: Matsuda insulin sensitivity index will be calculated using blood samples collected in the 2-hour postprandial period.

Measure: Matsuda insulin sensitivity index

Time: 2 hours

Description: Homeostasis model of insulin resistance will be calculated using blood samples collected in the 2-hour postprandial period.

Measure: Homeostasis model of insulin resistance

Time: 2 hours

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 rs1061325

Cell-based studies suggest that genetic variation in the CLTCL1 gene (which encodes for CHC22) at SNP rs1061325, influences GLUT4 retention.



HPO Nodes